Enanta Pharmaceuticals Inc

9EP

Company Profile

  • Business description

    Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

  • Contact

    4 Kingsbury Avenue
    WatertownMA02472
    USA

    T: +1 617 607-0800

    E: [email protected]

    https://www.enanta.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 September 2026

    Employees

    120

Stocks News & Analysis

stocks

Apple: Gemini partnership lets AI-worried investors breathe a sigh of relief

We believe a competitive—if not leading—AI feature suite will reinforce Apple’s wide-moat mobile device ecosystem.
stocks

ASX share ticks all the popular thematic boxes

The shares are overvalued as investors are overly excited about defence and gold exposure.
stocks

Bluescope offer knocked back by board

Our view on the potential for additional offers.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,138.5011.400.12%
CAC 408,332.1526.61-0.32%
DAX 4025,369.8535.49-0.14%
Dow JONES (US)49,590.2086.130.17%
FTSE 10010,143.262.560.03%
HKSE26,848.47239.990.90%
NASDAQ23,733.9062.560.26%
Nikkei 22553,549.161,609.273.10%
NZX 50 Index13,656.0527.24-0.20%
S&P 5006,977.2710.990.16%
S&P/ASX 2008,808.5017.200.20%
SSE Composite Index4,138.7626.53-0.64%

Market Movers